

FOR IMMEDIATE RELEASE

Transport And Nexus Announce Expansion Of The Board And Management Teams Through The Addition Of Key Personnel

Tom Amick, Former VP of Business Development for Johnson & Johnson's Investment Arm, Joins Transport's Board of Directors

Framingham, MA and Philadelphia, PA, March 23, 2005 – Transport Pharmaceuticals, Inc. (Transport) announced today that it has appointed Tom Amick, former vice president of business development at Johnson & Johnson Development Corporation, to the Company's Board of Directors. Transport operates under the management of neXus therapeutics, inc. (neXus), which has strengthened its senior team through the addition of several key hires and promotions within the firms' clinical, regulatory, and commercialization groups.

"Joining Transport's board made strategic sense to me, as I feel strongly that I can leverage my experience and network stemming from my two plus decades in the industry to support Transport in future collaborations," explained Tom Amick. "Transport has a streamlined business model and has advanced their drug-delivery technology, which was most recently validated by their licensing and collaboration agreement with GlaxoSmithKline for the device/drug combination system to deliver acyclovir to treat cold sores."

Most recently, Mr. Amick was the vice president of Johnson & Johnson Development Corporation. Prior to his time with J&J's investment arm, he worked with Janssen-Ortho, where he managed the entire J&J pharmaceutical and biotechnology portfolio for Canada, and was later appointed to president of Ortho Biotech Europe.

"This is an ideal juncture for Tom to join Transport. As our lead program, herpes labialis, advances into European Phase III trials, we will seek to expand our partnership efforts in the United States, as well as advance our programs for our anticipated next indications of onychomycosis and psoriasis," said Chuck Hadley, chairman of the board for Transport Pharmaceuticals.

Dennis Goldberg, chief executive officer of neXus, the management arm of Transport, followed by saying, "NeXus has also added key hires to the infrastructure in fundamental areas of commercialization, such as manufacturing and regulatory. These additions to the team provide us the breadth of expertise necessary to propel Transport's development."

The inherent virtual business model of Transport and neXus leverages their internal drug development management expertise, while utilizing external collaborations with academic institutions, pharmaceutical companies and clinical research organizations to advance the Transport's clinical and pipeline development efforts.

NeXus has recently strengthened these teams through the addition and promotion of the following members:

- Phil Friden has been promoted to vice president of research and development from his previous role as director.
- Henry Piel has been appointed director of quality assurance. He was the former compliance manager for Shire Biologics.
- Meri Bloom has been appointed director of regulatory affairs. Formerly, she was the regulatory affairs manager for Cubist Pharmaceuticals.
- Ed Doherty has been appointed director of manufacturing. He was previously director of manufacturing and process development for Nephros Therapeutics.
- Georgina Weber has been appointed associate director of clinical operations. She joins the team from Cato Research where she was senior clinical trials manager.

About Transport Pharmaceuticals, Inc.

Transport Pharmaceuticals, Inc. is developing a proprietary iontophoretic drug delivery technology applicable to multiple dermatological diseases, with an initial focus on herpes labialis, or cold sores. The company's lead product enables the delivery of high doses of acyclovir, an approved cold sore treatment, directly to impacted skin areas, addressing a primary barrier to effective treatment of herpes labialis. The company operates under the management of neXus therapeutics, Inc.

About Nexus Therapeutics, Inc.

NeXus therapeutics, inc. is a biopharmaceutical management company that employs an "essential product development" paradigm to enhance the development process of early stage drugs and combination products. NeXus was founded by Dennis I. Goldberg, Ph.D., a broadly experienced drug development executive, and employs a team of highly skilled chemistry, manufacturing, regulatory and development executives.

###